Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : TRC253
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : TRACON Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
TRACON Retains Global Rights to TRC253 Following Completion of a Phase 1/2 Trial
Details : The announcement came in the sense of Janssen Pharma's decision not to exercise their option to re-acquire TRC253's global rights after a analysis of the data in Phase 2.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 24, 2020
Lead Product(s) : TRC253
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : TRACON Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : TRC253
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 09, 2016
Lead Product(s) : TRC253
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Johnson & Johnson Innovative Medicine
Deal Size : Inapplicable
Deal Type : Inapplicable